HomeBusiness NewsDexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for...

Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with…

June 7, 2026

- Advertisement -

SAN DIEGO–(BUSINESS WIRE)–DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of Dexcom G7 leads to clinically and statistically significant reduction in A1C and improvement in glucose control among people with Type 2 diabetes…

Click here to view the original article.

Tags
Business Wire

- Advertisment -

Heard Partners with CAMFT to Bring Therapist-Specific Financial Support to California’s Marriage and…

KBRA Assigns Preliminary Ratings to Sequoia Mortgage Trust 2026-HYB2 (SEMT 2026-HYB2)

Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with…

Recently Viewed

Renter sparks outrage over home act ordered to be removed

Is this exciting healthcare stock a buy, hold or sell after rocketing 16% yesterday?

Lewi Brown’s style guide: The former NRL player turned fashion designer on his favourite brands, fashion icons and wardrobe essentials

Kyabram dump undergoes viral TikTok renovation masterpiece

FEATURED

Great White shark bites fishing boat off Sunshine Coast

Volcanic cloud from Whakaari White Island halts flights

Great Koala Count: Aussies urged to track sightings of iconic marsupials

POPULAR POSTS

Mangrove Loss Worldwide Is Now Reversing—with More, Denser Forests Than 20 Years Ago

2026 FIFA World Cup: Group D preview – USA, Australia, Turkiye and Paraguay

This CEO said three wines ruined his week. Has wellness gone too far?

POPULAR CATEGORY

FOLLOW US

Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with…

RELATED ARTICLES

Recently Viewed

FEATURED

POPULAR POSTS

POPULAR CATEGORY

FOLLOW US